Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies

Trial Profile

Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Talazoparib (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors BioMarin Pharmaceutical; Pfizer
  • Most Recent Events

    • 21 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 15 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top